Is breast cancer risk the same for all progestogens?

The 2012 Hormone Therapy Position Statement of The North American Menopause Society

(2016)   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Breast Cancer Risk in Postmenopausal Women Using Estradiol–Progestogen Therapy

(2014) Heli Lyytinen et al.   OBSTETRICS AND GYNECOLOGY

Progesterone – promoter or inhibitor of breast cancer

(2013) H. Kuhl et al.   CLIMACTERIC

Progression from ductal carcinoma in situ to invasive breast cancer: Revisited

(2013) Catherine F. Cowell et al.   Molecular Oncology

Risk of Breast Cancer by Type of Menopausal Hormone Therapy: a Case-Control Study among Post-Menopausal Women in France

(2013) Emilie Cordina-Duverger et al.   PLoS One

Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy womenin vivo

(2012) Daniel Murkes et al.   GYNECOLOGICAL ENDOCRINOLOGY

Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy

(2011) V. Beral et al.   JNCI-Journal of the National Cancer Institute

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement

(2010) Richard J. Santen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations

(2009) C. Schneider et al.   CLIMACTERIC

Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?

(2009) Agnès Fournier et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women

(2008) R. L. Prentice et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Transcriptional profiles of progestogen effects in the postmenopausal breast

(2008) Charles E. Wood et al.   BREAST CANCER RESEARCH AND TREATMENT